levodopa/carbidopa fairmed 100 mg/25 mg tabletes
fairmed healthcare gmbh, germany - levodopum, carbidopum - tablete - 100 mg/25 mg
levodopa/carbidopa fairmed 250 mg/25 mg tabletes
fairmed healthcare gmbh, germany - levodopum, carbidopum - tablete - 250 mg/25 mg
gabapentin strides 100 mg cietās kapsulas
strides pharma (cyprus) limited, cyprus - gabapentīns - kapsula, cietā - 100 mg
gabapentin strides 300 mg cietās kapsulas
strides pharma (cyprus) limited, cyprus - gabapentīns - kapsula, cietā - 300 mg
gabapentin strides 400 mg cietās kapsulas
strides pharma (cyprus) limited, cyprus - gabapentīns - kapsula, cietā - 400 mg
alfacalcidol strides pharma 0,25 mikrogrami mīkstās kapsulas
strides pharma (cyprus) limited, cyprus - alfakalcidols - kapsula, mīkstā - 0,25 µg
alfacalcidol strides pharma 0,5 mikrogrami mīkstās kapsulas
strides pharma (cyprus) limited, cyprus - alfakalcidols - kapsula, mīkstā - 0,5 µg
alfacalcidol strides pharma 1 mikrograms mīkstās kapsulas
strides pharma (cyprus) limited, cyprus - alfakalcidols - kapsula, mīkstā - 1 µg
kauliv
strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - kalcija homeostāze - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.
venclyxto
abbvie deutschland gmbh co. kg - venetoklakss - leikēmija, limfocītu, hroniska, b-šūna - antineoplastiski līdzekļi - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.